It remains important to further explore the role of PR in the context of breast cancer and to find more effective therapies for patients with ERα-positive/PR-negative cancer which still have a significantly worse prognosis than patients with ERα-positive/PR-positive tumors. This evidence concerns the gene PGR and breast carcinoma.